<DOC>
	<DOCNO>NCT02103257</DOCNO>
	<brief_summary>This randomise , control , multicentre trial design assess efficacy safety sequential icotinib plus chemotherapy versus single icotinib first-line treatment stage IIIB/IV lung adenocarcinoma patient EGFR mutation .</brief_summary>
	<brief_title>Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone First-line Treatment Stage IIIB/IV Lung Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Pathologic confirmation lung adenocarcinoma measurable disease , define least one lesion accurately measure least one dimension ( long diameter record CT ) Patients must previously untreated locally advanced metastatic NSCLC EGFR activate mutation ( exon 19 deletion , L858R ) require Eastern Cooperative Oncology Group performance status ( ECOG PS ) score 0 1 Prior chemotherapy treatment gefitinib , erlotinib , drug target EGFR Patients wildtype EGFR Any investigational agent permit Any evidence interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>